Objective: To analyze a putative relationship between white matter lesions (WMLs), risk factors for WMLs, and Alzheimer disease (AD) as measured with the surrogate marker CSF A␤42. Methods: The authors analyzed effects of acquired risk factors for cerebrovascular disease and WMLs on AD as measured with an intermediate marker, CSF A␤42.
Patients with cerebrovascular disease have increased risk for Alzheimer disease (AD). 1, 2 Established risk factors for vascular disease like hypercholesterolemia, hypertension, and hyperhomocysteinemia may increase the risk of sporadic AD, [3] [4] [5] and a reduced risk for AD after treatment of hypertension and hypercholesterolemia has been described. [5] [6] [7] [8] White matter lesions (WMLs), also associated with cognitive loss, 9, 10 are probably caused by distributed microangiopathy 11 and could be connected to diffuse cortical affection as seen in AD. 12 To distinguish between the effects of cerebrovascular disease and risk factors for vascular disease on AD, surrogate AD disease assessment must be made based on intermediate nonclinical markers and compared to degree of cerebrovascular disease and risk factors. Hyperhomocysteinemia, hypertension, and age are known risk factors for arteriolosclerosis and WMLs. 13, 14 Cerebral MRI combined with semiquantitative scales 15 allows more accurate grading of WMLs. New CSF markers for AD have diagnostic specificity and sensitivity of approximately 85% 16, 17 and predict development of clinical dementia in patients with mild cognitive impairment. 18 Experimental evidence suggests that the CSF A␤42 reduction seen in AD may be due to deposition in amyloid plaques, 19 rendering A␤42 a suitable intermediate marker for AD.
To investigate a putative link between WMLs and amyloid plaque formation, we combine cerebral MRI and CSF A␤42 analysis with measurements of the acquired risk factors hypertension, hypercholesterolemia, and hyperhomocysteinemia. APOE-ε4 status is included in the model, as this is a well-established genetic risk factor for sporadic AD 20 that might confound the analysis.
Methods. We included consecutive patients, 40 to 75 years of age, with subjective memory impairment or more advanced cognitive impairment, seen in our university-based memory unit between February 2000 and December 2004. Our routine investigation included cerebral MRI and CSF A␤42 measurements. A total of 142 patients were eligible. Of these, two patients did not have MRI scans done due to cardiac pacemakers, one due to a mechanic aortic valve, four due to other somatic conditions, and three due to psychiatric conditions. Two patients were excluded due to nonwhite background, leaving only white patients in the sample. Two patients had MRI scans done, but the hard copies were not found in the archives. One patient refused participation (i.e., did not allow the use of existing clinical data).
Of the remaining patients (N ϭ 127; participation rate 0.89; mean age 66 [range 44 to 75] years; 57 women, table) results of CSF analysis could not be obtained in six (two denied puncture, one did not undergo puncture due to low back pain, one did not undergo puncture for unknown reasons, and for two patients, the results of the analysis were not available).
There were no significant differences in age or gender between the excluded and included patient groups. All the included patients had whole brain sagittal T1-and axial T2-weighted MRI scans in a 1.0-Tesla Siemens Magnetom Harmony MRI scanner. The extent of WMLs was rated using a semiquantitative procedure, 15 and the score of four areas (frontal left/right and parietooccipital left/right) were added together, giving a maximal total score of 12 points. The rating was performed by two radiologists blinded to each other's results and to the clinical diagnosis. Mean values were used in cases of disagreement. CSF was obtained by lumbar puncture between vertebrae L3 and L4 or L4 and L5. CSF A␤42 levels were measured using standardized ELISA (Innotest ␤-Amyloid , Innogenetics, Belgium).
The statistical program package LISREL 8 (Scientific Software International, Chicago, IL) was used to perform path analysis 21 with the following variables: established and possible risk factors for WMLs and for reduced CSF A␤42 (age, hypertension, hyperhomocysteinemia, hypercholesterolemia, APOE-ε4), sum WML score, and reduced CSF A␤42. Age and sum WML score were used as a continuous variables. The number of APOE-ε4 alleles (0, 1, or 2) was used as an ordinal variable. Dichotomous variables were hypertension (systolic blood pressure Ն140 mm Hg or the use of antihypertensive medication), hypercholesterolemia (Ն8.0 mmol/L or the use of cholesterol-lowering medication), and hyperhomocysteinemia (Ն16.0 mmol/L) and CSF A␤42 (Յ450 ng/L).
Results. The table describes the characteristics of the patients, (mean Mini-Mental State Examination [MMSE]
score 24.2, SD ϭ 5.1). The coefficient of agreement between the two raters was good (weighted ϭ 0.75). The model that provided the best fit (minimum fit function 2 ϭ 2.73, p ϭ 0.74, df ϭ 5) included age, hypertension, and hyperhomocysteinemia as significant explanatory variables for sum WML score, and hypercholesterolemia, sum WML score and number of APOE-ε4 alleles as significant predictors of CSF A␤42 levels (figure). The WML score was 1.5 points higher for hypertensive patients than for nonhypertensive patients, and 1.9 points higher for patients with hyperhomocysteinemia than for those with normal homocysteine level. Thirty percent of the variance in sum WML score was explained by age, hypertension, and hyperhomocysteinemia. Having hypercholesterolemia raised the probability of low CSF A␤42 levels by 0.2, and for each point increase in WML score the probability of low CSF A␤42 levels increased by 0.03. These factors explained 9% of the variance in CSF A␤42 levels. When APOE-ε4 status was included, 16% of the variance in CSF A␤42 could be explained by the model. The sum WML score was not associated with hypercholesterolemia.
As described previously, 22 there was a significant effect of hyperhomocysteinemia on the amount of WMLs in men, but not in women (p ϭ 0.001 [B ϭ 3.365, SE ϭ 0.938] vs 0.055 [B ϭ 3.104, SE ϭ 1.583]). Age was not significantly related to CSF A␤42 levels.
Discussion. Our study supports previous evidence for links between WMLs and age, hypertension, and hyperhomocysteinemia, as well as between low CSF A␤42 and hypercholesterolemia and APOE-ε4. In addition, it suggests a link between WMLs and low CSF A␤42. Previous epidemiologic and experimental findings point to a link between ischemic damage in deep white matter and cortical Alzheimer pathology, but no causal relationship can be definitely established. The path analysis model implies a set of covariances among all pairs of variables. Adding, removing, or changing the direction of an effect (an arrow in the figure) means changing the set of regression equations. Therefore, path analysis tests whether postulated effects, based on the theory presented, correspond to the observed covariance structure of the data. It does not prove causality, but it tests whether the data set allows or denies the postulated effects.
Figure. A putative mechanism for a link between measured acquired risk factors, white matter lesion (WML), and reduced CSF A␤42 formation based on the model providing the best fit between the variables. Ischemia may induce formation of amyloid precursor protein (APP
Our results suggest that the association between risk factors and disease variables in part may be explained by effects as outlined in the figure. Cerebrovascular disease may aggravate cognitive loss, making otherwise subclinical AD discernable. In recent reports, CSF biomarkers have been shown to distinguish AD and vascular dementia. 23 CSF A␤42 levels are known to be inversely correlated with neuritic plaques 24 and to probably be stable over time in the normal population. 25 CSF A␤42 seems to discriminate AD with WMLs from vascular dementia (sensitivity 77%, specificity 80%). 26 It is, however, a surrogate marker, and reduced levels may also be seen in other neurodegenerative diseases. [27] [28] [29] [30] In a recent study, WMLs have been associated with hippocampal atrophy in AD. 12 Our study suggests that WMLs are also associated with amyloid deposition. Experimental findings have suggested plausible mechanisms that could account for this type of effect; ischemic changes in the surroundings of neuronal tracts might, e.g., lead to glial activation, formation of amyloid precursor protein (APP), and release of diffusible agents that may induce apoptosis. 22, [31] [32] [33] [34] [35] A different mechanism could be wallerian degeneration from damage to neuronal tracts by WMLs. Amyloid could be deposited in the disconnected cortical regions, or APP could be transported to cortical regions from the site of damage along neuronal tracts. 12, 36, 37 These hypotheses may be tested, e.g., by amyloid and white matter (tract) imaging.
In accordance with previous studies, we do not find that hypercholesterolemia is related to WMLs in this age group. 38, 39 Hypercholesterolemia is not only a vascular risk factor but has previously also been directly implicated in amyloid formation, possibly as a result of altered metabolism of APP. [40] [41] [42] WMLs and hypercholesterolemia could therefore independently contribute to low CSF A␤42 in subgroups of patients. 5 Also in accordance with previous studies, 14 our findings support the association between WMLs, hyperhomocysteinemia, and hypertension but not between the latter two and the intermediate marker for AD CSF A␤42.
WMLs are strongly related to age (figure). MRI scans of patients without known memory problems also indicate an enhanced accumulation of WMLs in this age group. 43 WMLs therefore probably affect the majority of the elderly population, and nonischemic cases are expected to be rare in older patients. According to previous studies, age-associated increased WML prevalence probably occurs prior to that of increased AD prevalence. 43, 44 In combination with the present observations, prospective studies to investigate a putative relationship between WMLs and the development of AD are needed.
